Difference between revisions of "Part:BBa K3924056"
Leslie Young (Talk | contribs) |
Leslie Young (Talk | contribs) |
||
Line 12: | Line 12: | ||
In order to heal the intestinal tract damage, one of notable symptoms of IBD, we adopted a special therapy expressing the therapeutic proteins controllably by <i>E.coli Nissle 1917</i> (EcN) in situ. The design is based on a ternary system: sensor - secretion peptide - therapeutic proteins.<br/> | In order to heal the intestinal tract damage, one of notable symptoms of IBD, we adopted a special therapy expressing the therapeutic proteins controllably by <i>E.coli Nissle 1917</i> (EcN) in situ. The design is based on a ternary system: sensor - secretion peptide - therapeutic proteins.<br/> | ||
[[Image:T--Tsinghua--General design of the treatment ternary system.png|center|600px|thumb|'''Figure 1: General design of the treatment ternary system''']] | [[Image:T--Tsinghua--General design of the treatment ternary system.png|center|600px|thumb|'''Figure 1: General design of the treatment ternary system''']] | ||
− | CsgA is one of candidate secretion peptides we screened out, which is a most essential element that help our therapeutic protein secrete outside the engineered bacteria and diffuse inside the patient's intestinal tract. It is the major unit of <i>Escherichia coli</i> curlin[1]. The sequence is mainly based on NCBI Gene ID: 949055 and modified by our condon preference system.<br/> | + | CsgA is one of candidate secretion peptides we screened out, which is a most essential element that help our therapeutic protein secrete outside the engineered bacteria and diffuse inside the patient's intestinal tract. It is the major unit of <i>Escherichia coli</i> curlin<sup>[1]</sup>. The sequence is mainly based on NCBI Gene ID: 949055 and modified by our condon preference system.<br/> |
==Functional Verification== | ==Functional Verification== | ||
For all candidate secretion peptides, we did codon analysis with our own software tool.(Figure 2) | For all candidate secretion peptides, we did codon analysis with our own software tool.(Figure 2) |
Latest revision as of 20:57, 21 October 2021
csgA-GFP
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal PstI site found at 371
- 12INCOMPATIBLE WITH RFC[12]Illegal PstI site found at 371
- 21COMPATIBLE WITH RFC[21]
- 23INCOMPATIBLE WITH RFC[23]Illegal PstI site found at 371
- 25INCOMPATIBLE WITH RFC[25]Illegal PstI site found at 371
- 1000COMPATIBLE WITH RFC[1000]
Usage and Biology
In order to heal the intestinal tract damage, one of notable symptoms of IBD, we adopted a special therapy expressing the therapeutic proteins controllably by E.coli Nissle 1917 (EcN) in situ. The design is based on a ternary system: sensor - secretion peptide - therapeutic proteins.
CsgA is one of candidate secretion peptides we screened out, which is a most essential element that help our therapeutic protein secrete outside the engineered bacteria and diffuse inside the patient's intestinal tract. It is the major unit of Escherichia coli curlin[1]. The sequence is mainly based on NCBI Gene ID: 949055 and modified by our condon preference system.
Functional Verification
For all candidate secretion peptides, we did codon analysis with our own software tool.(Figure 2)
As for csgA, the result of codon preference is shown in Figure 3.
The workflow of the verification of the secretion peptides' function is shown in Figure 4
The functional verification of secretion peptides was conducted by checking the fluorescence of the bacteria supernatant after centrifuging at 8000 rpm for 1 minute. The fluorescence is measured by microplate reader. The results are shown in Figure 5.
With RGP-GFP group (RGP is the plasmid backbone in our design) as a negative control, which doesn’t have any secretion peptide to diffuse GFP out of the protein, RGP-DsbA-GFP, however, does not show a significant difference. The fluorescence is slightly higher, but maybe due to the volatile lab environment, the significance cannot be shown. Nevertheless, we evaluate this part as a success.
With RGP-GFP group (RGP is the plasmid backbone in our design) as a negative control, which doesn’t have any secretion peptide to diffuse GFP out of the protein, RGP-CsgA-GFP shows a significant difference. Therefore, we evaluate this part as a success.
Reference
[1] Van Gerven, N., Klein, R. D., Hultgren, S. J., & Remaut, H. (2015). Bacterial amyloid formation: structural insights into curli biogensis. Trends in microbiology, 23(11), 693–706.